Integrin Agonists Enhancing Cell Retention in Regenerative Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell-based therapies face challenges in retaining exogenously delivered cells at damaged tissue sites due to low retention rates, which hinders regenerative medicine progress, as cells poorly adhere to tissues mediated by integrin receptors.
Innovation Solution
Development of chemical compounds that enhance integrin-mediated binding of cells to their respective ligands, specifically targeting integrins such as α4β1, α4β7, α5β1, αLβ2, and αVβ3, and ligands like VCAM-1, fibronectin, and ICAM-1, to improve cell retention and tissue homing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell-based therapy is used to treat tissue damage, then tissue regeneration is improved, but cell retention at target site is poor
Solution Approach 1:
The patent introduces integrin-activating compounds as intermediary substances that mediate between the injected cells and the target tissue. These compounds bind to integrin receptors on cell surfaces, activating them to enhance adhesion to extracellular matrix components at the injury site, thereby improving cell retention without changing the cells themselves
Solution Approach 2:
The patent changes the biochemical state of integrin receptors on cell surfaces by applying small molecule compounds that induce conformational changes in integrins. This activates the integrins from a low-affinity to high-affinity state, enabling stronger binding to ligands like fibronectin and vitronectin at the target tissue
2Area of stationary object
If cells are injected intravenously for systemic delivery, then coverage area is increased, but cell retention rate decreases significantly
Solution Approach 1:
The integrin-activating compounds serve as systemic mediators that prepare cells for homing regardless of delivery route. When cells are injected intravenously, these pre-applied compounds remain on cell surfaces or in circulation, enabling cells to recognize and adhere to target tissues throughout the body, thus maintaining high retention rates even with systemic delivery
Solution Approach 2:
The patent applies integrin-activating compounds to cells before injection or administers them systemically in advance. This preliminary activation of integrins ensures that cells are primed for adhesion before they encounter the target tissue, overcoming the dilution and dispersal effects of systemic delivery
3Quantity of substance
If local injection is used to improve cell retention, then cell retention increases, but treatment versatility is reduced
Solution Approach 1:
The integrin-activating compounds act as universal mediators that work regardless of delivery method. Whether cells are injected locally or systemically, the compounds facilitate adhesion through the same integrin-ligand interaction mechanism, providing consistent results across different treatment approaches and maintaining versatility
Data Source
AI summary
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.